Publication | Closed Access
Omalizumab (Xolair) for treatment of asthma.
20
Citations
0
References
2005
Year
AsthmaAllergyAllergy MedicineImmunologyAllergenImmunomodulatory TherapyPharmacotherapyImmunotherapyMedicineDrug AllergyClinical AllergyAllergic AsthmaConventional Therapy
Omalizumab is an immunomodulatory therapy for the control of symptoms in patients with moderate to severe allergic asthma uncontrolled with conventional therapy. Given its high cost, the requirement that it be administered in a physician’s office, and side effects, it is appropriate for use in only a small percentage of patients with asthma.